Share Twitter LinkedIn Facebook Email Celestia S. Higano, MD, shares the outcomes from the PROSPER and SPARTAN studies in non-metastatic castrate-resistant prostate cancer are impacting the standard of care.
MOASC Awards $25,000 Research Grant from AVEO Oncology to Dr. Peter Zang, MD of City of Hope 2025 Cary Presant, MD Investigator Award Prostate 4 Mins Read
Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD Prostate 2 Mins Read